Online inquiry

IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15676MR)

This product GTTS-WQ15676MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets EPCAM gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002354.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4072
UniProt ID P16422
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15676MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11310MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-522
GTTS-WQ11659MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ2462MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ2954MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ANB-011
GTTS-WQ4722MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ6624MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ13252MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ4910MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW